K3-EDTA differentially inhibits the growth of Candida strains according to their azole resistance status.


Journal

Medical mycology
ISSN: 1460-2709
Titre abrégé: Med Mycol
Pays: England
ID NLM: 9815835

Informations de publication

Date de publication:
01 Jun 2020
Historique:
received: 05 02 2019
revised: 21 06 2019
accepted: 25 06 2019
pubmed: 17 7 2019
medline: 4 2 2021
entrez: 17 7 2019
Statut: ppublish

Résumé

The diagnosis of the life-threatening invasive Candida infections is mainly established using culture of specimens that might be collected on different devices including ethylene diamine tetraacetic acid (EDTA)-coated tubes. Despite the knowledge that EDTA inhibits bacterial cultures, and its use to treat oral fungal infections, its impact on Candida cultures has not been completely assessed. This study aimed at assessing it on azole-resistant and azole-susceptible strains. Clinical and American Type Culture Collection (ATCC) strains for Candida albicans (CA), C. glabrata (CGS), C. krusei (CK), azole-susceptible and azole-resistant strains of C. glabrata (CGS and CGR), C. lipolytica (CL), and C. inconspicua (CI) were characterized using MALDI-TOF MS and susceptibility testing and then incubated (1) with serial dilutions of tripotassic EDTA (0%-500% of the concentration in a sample tube) for 2 hours before plating onto ChromID Can2 agar; (2) for 0, 2, 4, 6, 7, or 8 hours at EDTA concentrations at 20% and 33% before seeding; and (3) with sodium citrate or lithium heparinate instead of EDTA for 2 hours before plating. After 48 hours at 35°C, colony-forming units were automatically quantified. An inhibitory effect of EDTA was observed, at different concentrations, for CA (20%), CGS (100%), and CGR (500%) (P < .05), but none was observed for CL, CI, and CK. The effect increased with incubation duration, at a faster rate for azole-susceptible strains. K3-EDTA inhibits Candida growth and EDTA-coated tubes should not be used for mycological culture-based analyses. The correlation between EDTA inhibition and Candida azole-resistance offers perspectives for the development of selective agar and new antifungal strategies.

Identifiants

pubmed: 31309224
pii: 5532521
doi: 10.1093/mmy/myz080
doi:

Substances chimiques

Antifungal Agents 0
Azoles 0
Edetic Acid 9G34HU7RV0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

514-520

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.

Auteurs

Damien Dupont (D)

Hospices Civils de Lyon, Parasitology and Medical Mycology Laboratory, Infectious Agents Institute, Lyon, France.
Integrative Physiology of the Brain Arousal Systems, Centre de Recherche en Neurosciences de Lyon, INSERM U1028-CNRS UMR 5292, Facultée de Médecine, Université Claude Bernard Lyon 1, Lyon, France.

Pauline Tirard-Collet (P)

Hospices Civils de Lyon, Parasitology and Medical Mycology Laboratory, Infectious Agents Institute, Lyon, France.

Florence Persat (F)

Hospices Civils de Lyon, Parasitology and Medical Mycology Laboratory, Infectious Agents Institute, Lyon, France.

Jean Menotti (J)

Hospices Civils de Lyon, Parasitology and Medical Mycology Laboratory, Infectious Agents Institute, Lyon, France.

Emilie Josse (E)

Hospices Civils de Lyon, Parasitology and Medical Mycology Laboratory, Infectious Agents Institute, Lyon, France.

Martine Wallon (M)

Hospices Civils de Lyon, Parasitology and Medical Mycology Laboratory, Infectious Agents Institute, Lyon, France.
Integrative Physiology of the Brain Arousal Systems, Centre de Recherche en Neurosciences de Lyon, INSERM U1028-CNRS UMR 5292, Facultée de Médecine, Université Claude Bernard Lyon 1, Lyon, France.

Maxime Pichon (M)

Hospices Civils de Lyon, Virology Laboratory, Infectious Agents Institute, Lyon, France.
University Hospital of Poitiers,Bacteriology and Infection Control laboratory, Infectious Agents Department, Poitiers, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH